Suspending limitations on conference committee jurisdiction, S.B. No. 2308.

HR 1495 is a procedural resolution that suspends specific House Rules to allow the conference committee working on Senate Bill 2308 to make technical adjustments. It enables the committee to omit outdated definitions (like "Executive commissioner") and remove a grant program provision from the bill's text. The resolution does not change the policy substance of S.B. 2308, which would establish a consortium for FDA clinical trials of ibogaine to treat opioid and mental health conditions. This is purely a procedural step to streamline the conference committee's work on S.B. 2308.